COVID-19 Current Therapy Market Report 2025

The COVID-19 Current Therapy market size has declined steeply in recent years. It will decline from $5.87 billion in 2024 to $2.35 billion in 2025 at a compound annual growth rate (CAGR) of -60%. The decline in the historic period can be attributed to limited treatment options, varying treatment efficacy, supply chain disruptions, rapidly evolving scientific knowledge, emergence of variants.

The outbreak of the COVID-19 pandemic has significantly contributed to the growth of the COVID-19 current therapy market. The World Health Organization (WHO) declared the outbreak a global pandemic, and as of August 2022, reported global COVID-19 cases had reached 581.8 million. With no officially approved drug for COVID-19, there has been a substantial demand for repurposed drugs used in corona therapy. Countries worldwide are grappling with drug shortages, prompting manufacturers to scale up production to meet the surging global demand. The COVID-19 Treatment Acceleration Program (CTAP), initiated by the FDA, is a special emergency program designed to expedite the development of potential COVID-19 therapies for swift availability to patients.

The anticipated growth of the COVID-19 current therapy market is also driven by the expansion of healthcare infrastructure. The healthcare industry plays a crucial role in integrating sectors that provide products and services for curing, preventing, rehabilitating, and offering palliative care to patients. A robust healthcare infrastructure is essential for the effective implementation of COVID-19 therapies, ensuring timely patient care, supporting research and clinical trials, and providing essential resources for optimal treatment delivery. As an illustration, in May 2023, the American Health Care Association reported an increase in the number of hospitals in the US from 6,093 in 2022 to 6,129. Additionally, a report by the UK's Office for National Statistics revealed a 9.4% increase in healthcare spending in the UK between 2020 and 2021 in nominal terms, and a 9.7% increase in real terms. Hence, the expansion of the healthcare industry is a key driver propelling the growth of the COVID-19 current therapy market.

Convalescent Plasma Therapy has emerged as an experimental treatment for COVID-19 patients, involving the use of blood plasma from individuals who have recovered from the disease, known as convalescent plasma (CP). CP therapy is a passive antibody therapy where the isolated plasma, containing antibodies from recovered patients, is administered to individuals with severe disease to suppress virulence and improve clinical symptoms. The blood plasma of recovered COVID-19 patients contains antibodies that can combat the infection. The FDA recommends CP Therapy as an investigational product during public health emergencies. Approximately 2,004 participating sites adhering to a single expanded access protocol by the US FDA had been registered, with around 7,774 patients enrolled, and 3,809 of them undergoing convalescent plasma transfusion. The experimental nature of convalescent plasma therapy continues to attract attention, with its potential effectiveness depending on sufficient supporting data.

Leading companies in the COVID-19 current therapy market are increasingly concentrating on launching innovative products, such as COVID-19 oral antiviral treatments, to strengthen their competitive position. Antiviral treatment involves the use of medications designed to inhibit viral replication and spread within the body. For example, in April 2024, Invivyd, a U.S.-based company specializing in antibody-based therapies for severe viral infectious diseases, announced the launch of PEMGARDA. Following its emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA), PEMGARDA swiftly became available for commercial use. This treatment aims to prevent COVID-19 in individuals with moderate-to-severe immune compromise.

In March 2022, AstraZeneca, a UK-based biopharmaceutical company, developed Evusheld, a combination of tixagevimab and cilgavimab, which demonstrated a 77% reduction in the risk of symptomatic COVID-19 in the PROVENT Phase III trial. Unlike treatments such as Paxlovid, which are administered post-infection, Evusheld provides long-lasting protection, particularly for high-risk individuals. It is effective against multiple variants, including Omicron. This protection increased to 83% after six months, with no severe cases observed. The results emphasize its potential as a long-lasting pre-exposure prophylactic option. In Europe, the recommended dose of Evusheld is 150 mg of tixagevimab and 150 mg of cilgavimab.

Major companies operating in the COVID-19 current therapy market include Gilead Sciences, Inc., Ipca Laboratories Limited, Zydus Cadila, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, AbbVie, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Wallace Pharmaceuticals, Inc., Mylab Discovery Solutions, Kalbe Farma, He Qi Group Foundation, Beijing Jinwofu Bioengineering Technology Company, Zhejiang Orient Gene Biotech Co. Ltd, Transasia Bio Medicals, Vanguard Diagnostics, HLL Lifecare Limited, Voxtur Bio Ltd, Biocryst Pharma, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Inc., LAB-CARE Diagnostics, ImmunoScience, CPC Diagnostics, Sysmex Corporation, Atomo Diagnostics, Cellmid Limited, Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimmune, Hunan Lituo Biotechnology, Hangzhou Biotest Biotech, AmonMed Biotechnology, Getein Biotech, Beijing Tigsun Diagnostics, Vivacheck Lab, Seegene, SD Biosensor, Fujirebio, Siemens Healthcare Pte. Ltd., Senova, LetsGetChecked, Omega Diagnostics, Abingdon Health, Babylon, Motologic, F. Hoffmann-La Roche Ltd., Novacyt Group, AstraZeneca, Pfizer, Zentiva, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Amgen and AdaptiveBiotechnologies, BioNtech, Cytodyn, Heat biologics, Johnson&Johnson, Takeda pharmaceuticals, Vaxart, Vir Biotechnology, Victory Square Health, Abbott Molecular Inc., ACRO Biotech, Advagen Biotech Ltd, BD, Boditech Med, Inc., Cellex Inc., CerTest Biotec, S.L., Hi Technologies, BATM, BioMedomics Quant Lease, CapeBio, Astel Diagnostics, Canary Health Technologies, Thermo Fisher Scientific.

North America is the largest region in the COVID-19 current therapy market in 2024. Middle East is expected to be the fastest-growing region in the global COVID-19 current therapy market share during the forecast period. The regions covered in the COVID-19 current therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the COVID-19 current therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The COVID-19 current therapy market includes revenues earned by entities by tocilizumab, favipiravir, and ivermectin. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

COVID-19 Current Therapy encompasses the treatments and interventions aimed at managing symptoms and reducing the severity of COVID-19. These therapies are designed to relieve respiratory distress, prevent complications, and support recovery in those affected. Essential treatments include antiviral medications, corticosteroids, and supportive care.

Key drug categories in COVID-19 therapy comprise antivirals, monoclonal antibodies, corticosteroids, supplements, antimalarials, interferons, interleukin inhibitors, other anti-infective medications, and similar treatments. Antivirals are specific medications or compounds crafted to impede virus growth and replication, targeting various stages of the viral life cycle or disrupting viral processes. These drugs are administered via oral or intravenous routes and find application across hospitals, clinics, research institutes, and related sectors.

The COVID-19 current therapy market research report is one of a series of new reports that provides COVID-19 current therapy market statistics, including COVID-19 current therapy industry global market size, regional shares, competitors with a COVID-19 current therapy market share, detailed COVID-19 current therapy market segments, COVID-19 current therapy market trends and opportunities, and any further data you may need to thrive in the COVID-19 current therapy industry. This COVID-19 current therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.